


Patients with Established Cardiovascular Disease - Secondary Prevention



Lipid lowering therapy should be offered to all patients with established CVD

High Intensity Statin (HIS) for secondary prevention	
Atorvastatin	80mg
Rosuvastatin	20mg – 40mg (please note for rosuvastatin 40mg specialist supervision is recommended when this dose is initiated)

Dose may be limited, for example if:

- CKD: eGFR<60ml/min –recommended starting dose - atorvastatin 20mg
- Drug interactions
- Drug intolerance
- Older age / frailty

Use shared-decision making and incorporate patient preference in treatment and care decisions.

Women of childbearing age - as a precaution, most women are advised to stop taking statins for three months before trying to conceive, and during pregnancy. Refer to maternal medicine or lipid consultants for advice & guidance where appropriate.

***Where an individual qualifies for injectable therapies, as per NICE technology appraisals, consider these in preference to ezetimibe to prevent lipid levels being lowered but remaining above the LDL-C target and below thresholds for initiating injectable therapies.**